Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
P0.1 and Extubation Failure in Critically Ill Patients
- Conditions
- Critically IllMechanical VentilationWeaning Failure
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Cleveland Clinic Abu Dhabi
- Target Recruit Count
- 120
- Registration Number
- NCT05802745
- Locations
- 🇫🇷
Amiens University Hospital, Amiens, France
🇫🇷Centre Hospitalier d'Arras, Arras, France
🇫🇷Dijon University Hospital, Dijon, France
Correlation Between New O3 Regional Oximetry, Electroencephalography and the Somatosensory Evoked Potential in Carotid Endarterectomy Surgery
- Conditions
- Carotid Endarterectomy
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cleveland Clinic Abu Dhabi
- Target Recruit Count
- 10
- Registration Number
- NCT05267782
- Locations
- 🇦🇪
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
The Alternative Position for the SedLine® Sensor
- Conditions
- Depth of Anesthesia Monitoring
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Cleveland Clinic Abu Dhabi
- Target Recruit Count
- 40
- Registration Number
- NCT03947060
- Locations
- 🇦🇪
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies
- Conditions
- Renal Replacement Therapy
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Cleveland Clinic Abu Dhabi
- Target Recruit Count
- 200
- Registration Number
- NCT03636464
- Locations
- 🇦🇪
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
News
NeOnc Technologies Secures $50 Million Investment to Expand Brain Cancer Clinical Trials in MENA Region
NeOnc Technologies signed a non-binding term sheet with Quazar Investment for a $50 million equity investment to establish a UAE-based clinical platform focused on the Middle East and North Africa region.
M42, AstraZeneca, and SOPHiA GENETICS Launch UAE Liquid Biopsy Initiative to Transform Cancer Diagnosis
M42, AstraZeneca, and SOPHiA GENETICS announced a strategic collaboration to bring cutting-edge liquid biopsy testing to the UAE, enabling non-invasive genomic profiling through simple blood draws.
Cleveland Clinic Abu Dhabi Pioneers First GCC Breast Cancer Recurrence Trial with AstraZeneca
The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi becomes the first GCC facility to join a global Phase 3 trial testing a novel SERD anti-estrogen medication for breast cancer recurrence prevention.